Clinical Liver Disease

Latest Episodes:

Nonalcoholic fatty liver disease: Definitions, risk factors, and workup - Puneet Puri and Arun J. Sanyal – Article Reading Jul 07, 2013

Show notes

In this introduction to CLD’s special issue on NAFLD, Drs. Puri and Sanyal define nonalcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), addressing histology, risk factors, and work up.

Management of nonalcoholic steatohepatitis: Pharmacotherapy - Vlad Ratziu – Article Reading Jul 07, 2013

Show notes

Current guidelines do not recommend the use of hepatic pharmacological therapy in patients with steatosis alone. Instead, patients with NASH and significant liver disease (bridging fibrosis) are good candidates for therapy. Dr. Ratzui outlines the current guidelines, best available evidence, and potential pharmacologic management of the patient with NASH.

Liver transplantation and nonalcoholic fatty liver disease - Kymberly D. Watt – Article Reading Jul 07, 2013

Show notes

NASH-related cirrhosis is the third most common indication for transplantation in the current era and accounts for 10% to 13% of transplants performed. The need for liver transplantation in patients with NAFLD is growing. Dr. Watt explains the impact of disease recurrence on short- and medium-term survival and addresses management approaches necessary to improve long-term survival.

Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and management - Stavra A. Xanthakos and Rohit Kohli – Article Reading Jul 07, 2013

Show notes

Drs. Xanthakos and Kohli discuss the challenges in managing the pediatric patient with NAFLD, a growing patient population in both developed and developing countries. NAFLD in youth is often clinically silent and is discovered only upon screening or the incidental testing of serum aminotransferase levels.

Clinical Liver Disease - A new educational resource from the American Association for the Study of Liver Diseases Aug 22, 2012

Show notes

It is with great enthusiasm that we welcome you to an exciting new educational product. It is called Clinical Liver Disease, and it is an official digital educational resource from the American Association for the Study of Liver Diseases.

New targets and new agents - Article Reading Aug 21, 2012

Show notes

Patients infected with hepatitis C virus (HCV) and their physicians have long been awaiting a more tolerable and effective treatment regimen.

New targets and new agents - Interview with Andrew Muir Aug 21, 2012

Show notes

Interview with Andrew Muir.

The long-term horizon: Patients who will remain untreated in the era of triple therapy, Andrew Aronsohn - Article Reading Aug 21, 2012

Show notes

The direct-acting antivirals (DAAs) telaprevir and boceprevir have revolutionized hepatitis C virus (HCV) therapy by improving therapeutic outcomes for many patients.

The long-term horizon: Challenges - Interview with Don Jensen Aug 21, 2012

Show notes

Interview with Don Jensen.

The new standard of HCV therapy: Retreatment in experienced patients, Marc Ghany - Article Reading Aug 21, 2012

Show notes

The direct-acting antivirals (DAAs) telaprevir and boceprevir have revolutionized hepatitis C virus (HCV) therapy by improving therapeutic outcomes for many patients.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected

Our TOPPODCAST Picks

Follow Us

Stay Connected

Clinical Liver Disease

Related Podcasts

1

2

3

4

5

6